In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking Zocor OTC in the UK: A Testing Ground for US Strategy?

Executive Summary

The UK is set to become the first country in the world to see the launch of an OTC statin. In May 2004, UK regulators endorsed a switch application for Merck's once best-selling statin Zocor, genericized in 2003. Zocor Heart Pro will be targeted at an entirely different patient population to those currently on prescription statins. Tapping into this new market could in theory help Merck recoup some of the revenues it lost to generics in the prescription market. Yet the switch is perhaps less about generating small incremental UK revenues for Merck than about showing the FDA that making statins OTC is a viable and safe move.
Advertisement
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel